China Pharma Holdings (CPHI) Non-Current Debt (2013 - 2025)

China Pharma Holdings' Non-Current Debt history runs 13 years deep, the most recent figure standing at $1.3 million for Q2 2025.

• Quarterly Non-Current Debt fell 5.93% year-over-year to $1.3 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $1.3 million (down 5.93% YoY) and the FY2024 annual result came in at $1.4 million, down 1.47% from the prior year.
• Non-Current Debt was $1.3 million for Q2 2025 at China Pharma Holdings, down from $1.4 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $1.5 million in Q3 2022 and bottomed at $325072.0 in Q2 2021.
• A 5-year average of $1.2 million and a median of $1.4 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2021 — Non-Current Debt sank 83.56% — and 2022, when it jumped 92.5%.
• China Pharma Holdings' Non-Current Debt stood at $1.2 million in 2021, then jumped by 30.6% to $1.5 million in 2022, then decreased by 8.32% to $1.4 million in 2023, then dropped by 1.47% to $1.4 million in 2024, then retreated by 5.12% to $1.3 million in 2025.
• Business Quant data shows CPHI's Non-Current Debt at $1.3 million in Q2 2025, $1.4 million in Q1 2025, and $1.4 million in Q4 2024.